AHA Scientific Sessions 2026 Abstract
Real-World Eligibility for ApoC-III Inhibitor Therapy Among U.S. Adults with Severe Hypertriglyceridemia: A National Population-Based Analysis
Cross-sectional study of 11,153 peopleSevere hypertriglyceridemia
4 papers3 new in 30 days